Ethan Zohn Undergoes Stem-Cell Transplant

Ethan Zohn

Courtesy Jenna Morasca

"Ethan asked the doctor what was the record time for getting out of here, so he wants to beat that," Zohn's longtime girlfriend Jenna Morasca, who is staying with him at the hospital, tells PEOPLE.

"His doctor said there was no prize, and Ethan said, 'Yes, there is. You're going to tell the other patients that I made it out in three weeks.' "

Returning to the same ward where they stayed two years ago when Zohn was first diagnosed was difficult for the couple.

"No one wants to come back here. Even though the nurses and doctors are wonderful, this is one place where you really don't want to see anybody ever again," Morasca says. "Then starting the chemo and being attached to a pump that you're going to be attached to for the next three to five weeks made it very real."

On a happier note, Morasca says the support they've received from around the world has made all the difference. With help from family and friends, she was able to duck out of the hospital [Monday] to shoot the first episode of her new show, Fitness Guinea Pigs, which will air on YouTube's news channel.

And though Zohn's immune system is weakened, he can routinely have healthy visitors to his room, which he refers to as his "bubble." The two even created the Twitter account @Ethansbubble, which their friends can access to pen comical perspectives on the experience.

"We don't know who is actually writing the Tweets, so it makes it really fun," says Morasca. "It's all about thinking positively."

After the transplant, doctors will watch to make sure Zohn's body accepts the new stem-cells before releasing him from the hospital. Until then, the couple is making the best of their close quarters.

View original post here:
Ethan Zohn Undergoes Stem-Cell Transplant

'Survivor''s Ethan Zohn Gets Stem Cell Transplant

Survivor winner Ethan Zohn underwent a stem-cell transplant on Wednesday from one of his brothers in his continuing battle with Hodgkin's lymphoma.

Ethan's longtime girlfriend Jenna Morasca, who is staying with him in the hospital, tells People.com that they had returned to the same ward where they stayed when Zohn was first diagnosed two years ago. "No one wants to come back here," Jenna said. "Even though the nurses and doctors are wonderful, this is one place where you really don't want to see anybody ever again."

Survivor Winner Ethan Zohn's Cancer Returns

Jenna said this time around, Ethan asked the doctor what was the record time was "for getting out" and that he wanted to beat whatever that is. "His doctor said there was no prize, and Ethan said, 'Yes, there is. You're going to tell the other patients that I made it out in three weeks.'" Doctors will be closely watching Ethan to make sure his body accepts the new stem cells before he is released.

Jenna says for now the two are making the best of their close quarters. "I actually really like it, because he can't escape me," she tells People. "He's forced to be around me all the time and listen to everything I say. I'm like, 'What do you think of this hair?' and 'What about this lipstick color?' And he's over there pressing the pain medication pump button."

Cancer Survivor Ethan Zohn Stands Up to Cancer

Read the original here:
'Survivor''s Ethan Zohn Gets Stem Cell Transplant

'Survivor's' Zohn gets a stem-cell transplant

By Josh Grossberg, E! Online

Forget feeling like a million bucks. Ethan Zohn is feeling like a new man.

The "Survivor: Africa" champ underwent a stem-cell transplant Wednesday to treat a recurrence of his Hodgkin's lymphoma cancer--and he has his brother to thank for the immuno-boost.

Outwit, outlast, outplay has never quite meant so much.

More from E: Ethan Zohn and Jenna Morasca dye their hair pink to raise awareness for World Cancer Day

"Today I leap into a healthy new body. Today is the start of the rest of my life. Thank You to my bro Lee &all who have supported me. Love!" the reality star tweeted presumably before undergoing the transfusion.

And of course, Jenna Morasca, Zohn's girlfriend and winner of "Survivor: The Amazon," was right there with him the whole time.

"Thanks @JennaMorasca for being by my side. Love you," he added in a follow up.

Just before the transplant, Morasca wrote on Twitter: "Today @EthanZohn gets new stem cells &new cancer free life FOREVER! And we get our lives back. Send positive healing vibes #getbetterethan"

More from E: 'Survivor' Ethan Zohn's cancer returns

See the rest here:
'Survivor's' Zohn gets a stem-cell transplant

A*STAR Scientists Make Groundbreaking Discovery on Stem Cell Regulation

Embryonic stem cells hold great potential for the development of cellular therapies, where stem cells are used to repair tissue damaged by disease or trauma. This is due to their unique ability to renew themselves and differentiate into any specific types of cell in the body. One of the challenges with cellular therapies is ensuring that ESCs are fully and efficiently differentiated into the correct cell type. This study sheds light on understanding how ESCs are regulated, which is essential to overcome these challenges and turn the vision of cell therapies into reality.

Using a mouse model, the team of scientists from IMB showed that high levels of Amd1 , a key enzyme in the polyamine synthesis pathway, is essential for maintenance of the ESC state and self renewal of ESCs. To further demonstrate the critical role of Amd1 in ESC self-renewal, the scientists showed that increasing Amd1 levels led to delayed ESC differentiation. The research also revealed that downregulation of Amd1 was necessary for differentiation of ESCs into neural precursor cells and that Amd1 is translationally regulated by a micro-RNA (miRNA), the first ever demonstration of miRNA-mediated regulation of the polyamine pathway.

While the polyamine pathway is well established and polyamines are known to be important in cancer and cell proliferation, their role in ESC regulation until now was unknown. This novel discovery, linking polyamine regulation to ESC biology, came about when the team set up a genome-wide screen to look for mRNAs under translational control in order to identify new regulators of ESC differentiation to neural precursor cells.

Dr Leah Vardy, Principle Investigator at the IMB and lead author of the paper, said, "The polyamines that Amd1 regulate have the potential to regulate many different aspects of self renewal and differentiation. The next step is to understand in more detail the molecular targets of these polyamines both in embryonic stem cells and cells differentiating to different cellular lineages. It is possible that manipulation of polyamine levels in embryonic stem cells through inhibitors or activators of the pathway could help direct the differentiation of embryonic stem cells to more clinically useful cell types."

Prof. Birgitte Lane, Executive Director of IMB, said, "This is a fine piece of fundamental research that will have breakthrough consequences in many areas and can bring about far-reaching applications. Developing cellular therapies is just one long-term clinical benefit of understanding ESC biology, which can also help develop stem cell systems for disease modeling, developing new drugs as well as a tool for researchers to answer other biological questions."

Notes for editors: The research findings can be found in the 1st March issue of Genes and Development under the title, "AMD1 is essential for ESC self-renewal and is translationally down-regulated on differentiation to neural precursor cells" by Dawei Zhang (1,4), Tianyun Zhao (1,4), Haw Siang Ang (2), Peini Chong (1), Ryotaro Saiki (3), Kazuei Igarashi (3), Henry Yang (2), and Leah A. Vardy (1,5).

1. Institute of Medical Biology, A*STAR, Singapore 2. Cancer Science Institute, National University of Singapore 3. Graduate School of Pharmaceutical Sciences, Chiba University, Japan 4. These authors contributed equally to this work 5. Corresponding author

About the Institute of Medical Biology (IMB)

IMB is one of the Biomedical Sciences Institutes of the Agency for Science, Technology and Research (A*STAR). It was formed in 2007, the 7th and youngest of the BMRC Research Institutes, with a mission to study mechanisms of human disease in order to discover new and effective therapeutic strategies for improved quality of life.

IMB hosts 20 research teams of international excellence in stem cells, genetic diseases, cancer and skin and epithelial biology, and works closely with clinical collaborators to target the challenging interface between basic science and clinical medicine. Its growing portfolio of strategic research topics is targeted at translational research on the mechanisms of human diseases, with a cell-to-tissue emphasis that can help identify new therapeutic strategies for disease amelioration, cure and eradication.

See the original post here:
A*STAR Scientists Make Groundbreaking Discovery on Stem Cell Regulation

:: 01, Mar 2012 :: A*STAR SCIENTISTS MAKE GROUNDBREAKING DISCOVERY ON STEM CELL REGULATION

MEDIA RELEASE

A*STAR Scientists Make Groundbreaking Discovery on Stem Cell Regulation

New link between polyamine levels and embryonic stem cell state deepens our understanding of embryonic stem cell regulation which is a key step in bringing cellular therapies from the laboratory to the clinic.

1. A*STAR scientists have for the first time, identified that precise regulation of polyamine[1] levels is critical for embryonic stem cell (ESC) self-renewal the ability of ESCs to divide indefinitely and directed differentiation. This paper is crucial for better understanding of ESC regulation and was published in the journal Genes & Development on 1st March by the team of scientists from the Institute of Medical Biology (IMB), a research institute under the Agency for Science, Technology and Research (A*STAR).

2. Embryonic stem cells hold great potential for the development of cellular therapies, where stem cells are used to repair tissue damaged by disease or trauma. This is due to their unique ability to renew themselves and differentiate into any specific types of cell in the body. One of the challenges with cellular therapies is ensuring that ESCs are fully and efficiently differentiated into the correct cell type. This study sheds light on understanding how ESCs are regulated, which is essential to overcome these challenges and turn the vision of cell therapies into reality.

3. Using a mouse model, the team of scientists from IMB showed that high levels of Amd1[2], a key enzyme in the polyamine synthesis pathway, is essential for maintenance of the ESC state and self renewal of ESCs. To further demonstrate the critical role of Amd1 in ESC self-renewal, the scientists showed that increasing Amd1 levels led to delayed ESC differentiation. The research also revealed that downregulation of Amd1 was necessary for differentiation of ESCs into neural precursor cells and that Amd1 is translationally regulated by a micro-RNA (miRNA), the first ever demonstration of miRNA-mediated regulation of the polyamine pathway.

4. While the polyamine pathway is well established and polyamines are known to be important in cancer and cell proliferation, their role in ESC regulation until now was unknown. This novel discovery, linking polyamine regulation to ESC biology, came about when the team set up a genome-wide screen to look for mRNAs under translational control in order to identify new regulators of ESC differentiation to neural precursor cells.

6. Dr Leah Vardy, Principle Investigator at the IMB and lead author of the paper, said, The polyamines that Amd1 regulate have the potential to regulate many different aspects of self renewal and differentiation. The next step is to understand in more detail the molecular targets of these polyamines both in embryonic stem cells and cells differentiating to different cellular lineages. It is possible that manipulation of polyamine levels in embryonic stem cells through inhibitors or activators of the pathway could help direct the differentiation of embryonic stem cells to more clinically useful cell types.

7. Prof. Birgitte Lane, Executive Director of IMB, said, This is a fine piece of fundamental research that will have breakthrough consequences in many areas and can bring about far-reaching applications. Developing cellular therapies is just one long-term clinical benefit of understanding ESC biology, which can also help develop stem cell systems for disease modeling, developing new drugs as well as a tool for researchers to answer other biological questions.

Notes for editor:

Originally posted here:
:: 01, Mar 2012 :: A*STAR SCIENTISTS MAKE GROUNDBREAKING DISCOVERY ON STEM CELL REGULATION

Meet Cord Blood Registry’s Leader of Laboratory Operations – Video

28-02-2012 16:31 Learn more about cord blood stem cells here http://www.cordblood.com Cord Blood Registry takes pride in leading the cord blood banking industry with its state-of-the-art lab. Meet Kristen, who leads the effort to make sure we're providing our clients with the best once their babies' stem cells arrive in Tucson. Kristen is one of the many people who make sure that, from that first phone call to the day your baby's stem cells are collected and stored, you receive the industry's best service and support. For more information on CBR's processes, visit: http://www.cordblood.com

Originally posted here:
Meet Cord Blood Registry's Leader of Laboratory Operations - Video

Women Can Make New Eggs After All, Stem-Cell Study Hints

Women may make new eggs throughout their reproductive yearschallenging a longstanding tenet that females are born with finite supplies, a new study says. The discovery may also lead to new avenues for improving women's health and fertility.

A woman has two ovaries, which release eggs during her monthly ovulation.(Learn more about the human body.)

Previous research had suggested that a woman is born with all the egg cells she will ever have in her lifetime.

But in recent experiments, scientists discovered a new type of stem cell in the ovaries thatwhen grown in the labgenerates immature egg cells.The same immature cells isolated from adult mouse ovaries canturn into fertile eggs.

Stem cells,found in embryos and certain adult body tissues, have the potential to grow into many different types of cells.

(See"Liposuction Fat Turned Into Stem Cells, Study Says.")

The finding reinforces the team's previous experiments in mice, which had identified a new type of ovarian stem cell that renews a female mouse's source of eggs throughout its fertile years.

That study, published in the journal Nature in 2004, was the "first to reach the conclusion that this long-held belief in our fieldthat young girls are given a bank account at birth that you can no longer deposit eggs to, just withdraw fromwas no longer true," said study leaderJonathan Tilly.

By reinforcing these earlier results in people, the new study is a "big step forward" from the mouse work, emphasized Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital in Boston.

From a purely biological perspective, the concept that a woman would continually generate new eggs during her reproductive years makes sensesince men constantly replenish their sperm, Tilly added. (Read how men produce 1,500 sperm a second.)

Link:
Women Can Make New Eggs After All, Stem-Cell Study Hints

Cryo-Cell Reports Financial Results for Fiscal 2011

OLDSMAR, Fla., Feb. 29, 2012 /PRNewswire/ --Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for its fiscal year 2011.

"Cryo-Cell fiscal 2011 results are indicative of a company that is in the process of making many organizational and operational improvements," stated David Portnoy, Cryo-Cell's Chairman and Co-CEO. "Although the implementation of these steps is still in the early stages, we are encouraged in our belief that our goals will be achieved."

Mark Portnoy, Cryo-Cell's Co-CEO, added, "With the transition of the new Board of Directors last year, the Company made significant changes over the last six months. We are continuing to improve the IT systems and website, and have embarked on a major rebranding/marketing effort. Although these efforts have increased our expenses, we have balanced that somewhat with cost reductions. We feel these are appropriate and necessary investments for the Company's future. In addition, the Company has implemented its previously announced stock repurchase plan, and to date, has repurchased 415,117 shares on the open market and in private transactions."

Financial Results

Consolidated revenues for fiscal year ended 2011 were approximately $17.9 million compared to approximately $17.7 million for fiscal 2010. The revenues for fiscal 2011 consisted of approximately $16.5 million in processing and storage fee revenue and approximately $1.4 million in licensee income compared to approximately $16.2 million in processing and storage fee revenue and approximately $1.5 million in licensee income for fiscal 2010. Licensee income for the fiscal year ended November 30, 2011 primarily consisted of approximately $1.3 million in royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The remaining licensee income of approximately $41,000 related to installment payments of non-refundable up-front license fees from the licensees of the Company's umbilical cord blood program in Costa Rica, Nicaragua and Germany. Licensee income for the fiscal year ended November 30, 2010 primarily consisted of approximately $1.3 million in royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. The remaining licensee income of $175,000 related to installment payments of non-refundable up-front license fees from the licensees of the Company's umbilical cord blood program in Chile, Colombia, Peru, Nicaragua, Pakistan, Curacao, Bonaire, St. Maarten, Aruba and Suriname.

The Company reported a net loss in fiscal 2011 of approximately ($2.1 million), or ($0.18) per basic and diluted share, compared to net income of approximately $3.5 million, or $0.29 per basic and diluted share in fiscal 2010. The decrease in net income for fiscal 2011 principally resulted from a 31% increase in marketing, general and administrative expenses. The increase was due in part to an increase in fees associated with the annual meeting. The total fees expended for the 2011 Annual Meeting were approximately $957,000. The increase was also due to a write-off of approximately $211,000 for abandoned patents and trademarks due to the decision of management to discontinue pursuing certain patents and trademarks and an approximate $627,000 impairment of previously capitalized costs associated with the development of internal use computer software. Also, included in marketing, general and administrative expenses is approximately $950,000 related to an accrual of severance in accordance with the employment agreement of Mercedes Walton, the Company's former Chairman and CEO dated August 15, 2005, as amended July 16, 2007 because the circumstances relating to her termination are in dispute. Per the employment agreement, Ms. Walton would be entitled to severance in the amount up to $950,000 related to lost salary, bonuses and benefits if she had not been terminated for Cause, as defined in the agreement. The Company believes that Ms. Walton has not earned the right to this severance and intends to defend this position. Excluding all one-time charges noted above, the Company had net income before one-time charges in fiscal 2011 of approximately $645,000, or $0.05 per basic and diluted share before one-time charges. Included in the net income of $3.5 million for fiscal 2010 was the reversal of approximately $1.7 million of the Company's valuation allowance for income taxes. The decision to reverse a portion of the allowance was based on the Company's historical operating performance and future projections of taxable income.

As of November 30, 2011, the Company had approximately $7.3 million in cash, cash equivalents, marketable securities and other investments compared to $9.5 million as of November 30, 2010, representing a 23% decrease. The decrease is primarily attributable to the funding of a Grantor trust in the amount of $2,500,000 to escrow amounts that may become payable to the Company's former Chief Executive Officer and other executive officers of the Company under their respective Employment Agreements as a result of a change in control. The Company had no long-term debt at the end of fiscal 2011.

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. was founded in 1989 and was the world's first private cord blood bank to separate and store stem cells in 1992. Today, Cryo-Cell has over 240,000 clients worldwide from 87 countries. Cryo-Cell's mission is to provide our clients with the premier stem cell cryopreservation service and to support the advancement of regenerative medicine.

Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility, is ISO 9001:2008 certified and accredited by the AABB. Cryo-Cell is a publicly traded company. OTC:QB Markets Group Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.cryo-cell.com.

Continued here:
Cryo-Cell Reports Financial Results for Fiscal 2011

Nuvilex Reveals Goldman Small Cap Research Cites Groundbreaking Cancer Therapy in Updating Buy Recommendation

SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, announced today Goldman Small Cap Research has reissued its buy recommendation on Nuvilex with a short term price target of $0.50 per share.

According to the research report prepared by Goldman, The current share price represents but a fraction of its true value, in our view. With recently increased interest and valuation in the pancreatic cancer treatment arena, we believe that Nuvilex is worth $0.20 just on the oncology therapies alone and that the shares will reach $0.50 in the next six months. Looking ahead, as milestone events occur, $1.00 per share is within reach over the next 12-18 months.

Goldman bases this value projection, in part, on the pending acquisition of SG Austria assets, and with it complete control over the cell encapsulation technology that forms the backbone of Nuvilexs planned biotechnology development. The report states in part the following:

Following execution of the SG Austria asset acquisition, we expect to see a flurry of events and progress on the development side which will serve as catalysts, including when management submits its protocol for the next stage pancreatic cancer trial. We would not be surprised to see the stock break through the $0.50 price on such news as well as progress on the next stage of trials for other therapies.

One reason we are so convinced of the great buying opportunity is the fact that pancreatic cancer treatments are currently at the forefront of the biotech space and are enjoying very high valuations. Although Nuvilex is a not a drug producer, but an existing therapy enhancer through the use of its live cell encapsulation enhancement platform, the timing of these milestone events could not be better for Nuvilex and a re-valuation of its offering.

The Goldman report also compares alternative oncology therapies, including Gemzar from Threshold Pharmaceuticals and Merrimack Pharmaceuticals drug encapsulation technology, noting that, contrary to these treatments, the Nuvilex live-cell encapsulation technology is not limited to one specific use, but can be adapted to use for a host of cell types. The report states, Its difficult to compare apples-to-apples in this space as Nuvilex is the only firm utilizing live-cell encapsulation therapy for cancer, while all the other treatments are based upon a particular drug usage. Contrasting the results of different Phase II clinical trials, the Goldman report comments that the pancreatic cancer therapy, based on completed Phase 1/2 data, appears to have yielded statistically greater results than competing technologies.

Commenting on The Goldman Report, Nuvilex Chief Executive Officer, Dr. Robert Ryan, stated, The report did an excellent job highlighting the value and capabilities of our cell encapsulation technology, not just for cancer therapy, but also for the vast array of treatments where live-cell encapsulation can aid multiple diseases. In the case of the completed cancer trials, it generated superior results with lower drug dosages, and reduced chemotherapeutic side effects. As we move forward with diabetes and stem cell therapy treatments, we are confident our success will, as Goldman predicts prompt leaders in multiple treatment segments to partner with Nuvilex in order to maintain their respective market shares.

Investors are recommended to study the Goldman Research Report for a detailed review and valuation methodology regarding Nuvilex.

About Nuvilex

See the original post here:
Nuvilex Reveals Goldman Small Cap Research Cites Groundbreaking Cancer Therapy in Updating Buy Recommendation

Stem-Cell Therapy Takes Off in Texas

By David Cyranoski of Nature magazine

With Texas pouring millions of dollars into developing adult stem-cell treatments, doctors there are already injecting paying customers with unproven preparations, supplied by an ambitious new company.

The US Food and Drug Administration (FDA) has not approved any such stem-cell treatment for routine clinical use, although it does sanction them for patients enrolled in registered clinical trials. Some advocates of the treatments argue, however, that preparations based on a patient's own cells should not be classed as drugs, and should not therefore fall under the FDA's jurisdiction.

There are certainly plenty of people eager to have the treatments. Texas governor Rick Perry, for instance, has had stem-cell injections to treat a back complaint, and has supported legislation to help create banks to store patients' harvested stem cells.

One company that has benefited from this buoyant climate is Celltex Therapeutics, which "multiplies and banks" stem cells derived from people's abdominal fat, according to chairman and chief executive David Eller. Its facility in Sugar Land, just outside Houston, opened in December 2011 and houses the largest stem-cell bank in the United States.

Celltex was founded by Eller and Stanley Jones, the orthopaedic surgeon who performed Perry's procedure, and it uses technology licensed from RNL Bio in Seoul. Because clinical use of adult-stem-cell treatments are illegal in South Korea, RNL has since 2006 sent more than 10,000 patients to clinics in Japan and China to receive injections.

Celltex says that although it processes and banks cells, it does not carry out stem-cell injections. It declined to answer Nature's questions about whether its cells have been used in patients. But there is evidence that the company is involved in the clinical use of the cells on US soil, which the FDA has viewed as illegal in other cases.

Public hype

In addition to the publicity surrounding Perry's treatment, a woman named Debbie Bertrand has been blogging about her experiences during a five-injection treatment with cells prepared at Celltex. Her blog (http://debbiebertrand.blogspot.com) hosts photographs of herself alongside Jones; Jennifer Novak, a Celltex nurse; Jeong Chan Ra, chief executive of RNL Bio; and her doctor, Jamshid Lotfi, a neurologist who works for the United Neurology clinic in Houston. Another photo is captioned: "My cells are being processed in here for my next infusion!!!" A third shows Bertrand, Lotfi and a physician called Matthew Daneshmand, who is, according to the caption, injecting Bertrand's stem cells into an intravenous drip, ready for the infusion. Nature has been unable to contact Bertrand.

Lotfi says that he has administered cells processed by Celltex to more than 20 people. "Five or six" -- including Bertrand -- have multiple sclerosis and "four or five" have Parkinson's disease, he says. Lotfi explains that patients sign up for treatment by contacting Novak, and that cells are prepared by removing about five grams of fat -- containing roughly 100,000 mesenchymal stem cells -- from the patient's abdomen. Over a three-week period, the cells are cultured until they reach about 800 million cells. Lotfi says that patients get at least three injections of 200 million cells each, and that the cells do not take effect for a few months. According to Lotfi, Celltex charges US$7,000 per 200 million cells, and pays Lotfi $500 per injection.

See the article here:
Stem-Cell Therapy Takes Off in Texas